TCGA-AR-A0TP-01A-11R-A084-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 142
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.460
- HEDGEHOG_SIGNALING+0.410
- G2M_CHECKPOINT+0.360
- HYPOXIA+0.330
- WNT_BETA_CATENIN_SIGNALING+0.330
- MITOTIC_SPINDLE+0.300
- MYC_TARGETS_V2+0.270
- TGF_BETA_SIGNALING+0.270
- MYC_TARGETS_V1+0.260
- PROTEIN_SECRETION+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.450
- IL6_JAK_STAT3_SIGNALING-0.430
- INFLAMMATORY_RESPONSE-0.340
- ESTROGEN_RESPONSE_EARLY-0.280
- FATTY_ACID_METABOLISM-0.270
- COMPLEMENT-0.250
- OXIDATIVE_PHOSPHORYLATION-0.250
- BILE_ACID_METABOLISM-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0I6-01A-11R-A034-07 | — | E | 0.890 |
| 2 | 20130126.TNBC | — | E | 0.887 |
| 3 | TCGA-51-4081-01A-01R-1100-07 | — | cohortSQ2 | 0.885 |
| 4 | 20110025.TNBC | — | E | 0.878 |
| 5 | SRR8613771 | — | E | 0.878 |
| 6 | TCGA-AN-A0FX-01A-11R-A034-07 | — | E | 0.877 |
| 7 | C3N-03662 | — | cohortSQ2 | 0.869 |
| 8 | TCGA-21-5783-01A-41R-2187-07 | — | cohortMD1 | 0.838 |
| 9 | 2b2c2ebc-e83c-442e-88ae-1a2569ac892f | — | — | 0.837 |
| 10 | 20120162.TNBC | — | E | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.180 | Inavolisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |